Wave Life Sciences Ltd. (WVE)
undefined
undefined%
At close: undefined
13.44
0.07%
After-hours Dec 13, 2024, 05:19 PM EST

Company Description

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform.

It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression.

The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders.

In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases.

It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London.

The company was incorporated in 2012 and is based in Singapore.

Wave Life Sciences Ltd.
Wave Life Sciences Ltd. logo
Country SG
IPO Date Nov 11, 2015
Industry Biotechnology
Sector Healthcare
Employees 266
CEO Dr. Paul B. Bolno M.B.A., M.D.

Contact Details

Address:
Marina One East Tower
Singapore,
SG
Website https://www.wavelifesciences.com

Stock Details

Ticker Symbol WVE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001631574
CUSIP Number Y95308105
ISIN Number SG9999014716
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dr. Paul B. Bolno M.B.A., M.D. President, Chief Executive Officer & Director
Dr. Chandra Vargeese Ph.D. Chief Technology Officer
Kyle B. Moran CFA Chief Financial Officer & Principal Accounting Officer
Anne-Marie Li-Kwai-Cheung Chief Development Officer
Daryn Lewis Senior Vice President & Head of Human Resources
Dr. Christopher Francis Ph.D. Senior Vice President of Corporate Development & Head of Emerging Areas
Dr. Erik Ingelsson M.D., Ph.D. Chief Scientific Officer
Dr. Sridhar Vaddeboina Ph.D. Senior Vice President of Chemistry, Manufacturing & Controls
Kate Rausch Head of Investor Relations
Linda Rockett J.D. Senior Vice President & General Counsel

Latest SEC Filings

Date Type Title
Nov 27, 2024 4 Filing
Nov 20, 2024 8-K Current Report
Nov 15, 2024 4 Filing
Nov 13, 2024 4 Filing
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 12, 2024 S-8 Filing
Nov 12, 2024 S-8 Filing
Nov 12, 2024 S-3ASR Automatic shelf registration statement of securiti...
Nov 08, 2024 SC 13G Statement of acquisition of beneficial ownership b...